Taken together, these experiments revealed differences in the sensitivities and responses to pharmacological inhibition of NFkB and NOTCH pathways, indicating that targeted gene deregulations in CTCL subsets carry significant therapeutic potential. The gene discussed is NFKB1; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.